News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Acorda Therapeutics (ACOR) Appoints Andrew Hindman As Chief Business Development Officer


5/14/2014 7:19:23 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Acorda Therapeutics, Inc. (Nasdaq:ACOR) has appointed Andrew Hindman as Chief Business Development Officer.

“Business development is a key to Acorda’s growth strategy, and I am delighted that Andrew will lead our efforts to acquire new assets that add to our promising pipeline. Andrew is a highly talented, experienced business leader with an outstanding track record of identifying and completing value-creating strategic transactions,” said Ron Cohen, M.D., Acorda’s President and CEO.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES